Welcome to our dedicated page for Sanofi FR SEC filings (Ticker: SNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanofi filings document a foreign biopharmaceutical issuer whose American depositary shares represent interests in ordinary shares. Its SEC record includes Form 6-K reports and Form 20-F annual reporting that incorporate parent-company press releases, financial reports, governance materials and ADR-related disclosure.
Sanofi’s filings cover operating results, research and development spending, product and pipeline updates, regulatory approvals and designations, and therapeutic areas such as immunology, vaccines, rare diseases, oncology, respiratory disease and diabetes. They also document bond issuance under its Euro Medium Term Note programme, share buyback activity, annual meeting resolutions, board and executive appointments, risk factors and capital-structure matters.
Amundi and Amundi Asset Management report beneficial ownership of 61,769,803 shares of Sanofi (common stock and ADRs), representing 5.03% of the class. The filing shows no sole voting or dispositive power and records shared voting power of 29,534,426 shares and shared dispositive power of 61,769,803 shares.
The filing discloses that 26,790,332 shares are held through an employee FCPE on which Amundi does not exercise voting rights; those voting rights are exercised by the FCPE supervisory board where employee representatives hold the majority. The reporting persons are organized in France and filed this Schedule 13G/A under the Securities Exchange Act.
Sanofi (SNY) has filed a July 2025 Form 6-K that incorporates two press releases.
- 16 Jul 2025: Investigational complement inhibitor SAR446597 received FDA Fast Track designation for geographic atrophy secondary to age-related macular degeneration, potentially accelerating development and review.
- 22 Jul 2025: Sanofi announced an agreement to acquire Vicebio, a private company developing respiratory vaccines, to broaden its vaccines pipeline.
No financial statements, deal value, or timing details are included in the filing. Nonetheless, the regulatory milestone and pipeline-expanding acquisition underscore Sanofi’s strategic emphasis on specialty therapies and vaccines, areas that management views as key long-term growth drivers.
Sanofi (SNY) filed a Form 6-K to notify investors that its investigational monoclonal antibody riliprubart has received orphan-drug designation in two major markets during June 2025:
- United States (FDA) – for the prevention of antibody-mediated rejection in solid-organ transplantation (Press Release 25 Jun 2025).
- Japan (MHLW) – for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) (Press Release 30 Jun 2025).
Orphan-drug status can confer regulatory incentives such as market exclusivity (7 years in the U.S., up to 10 years in Japan), tax credits, fee waivers and a potentially faster approval pathway. Although the filing does not disclose clinical data, financial terms or timelines, the dual designation signals regulatory validation of riliprubart’s potential across two distinct immunological indications. No other material transactions, financial results or strategic changes are included in this 6-K.
Sanofi has reported three significant developments in their drug portfolio through Form 6-K filed on June 28, 2025:
- Dupixent superiority demonstrated over Xolair (omalizumab) in the first-ever phase 4 head-to-head respiratory study for treating chronic rhinosinusitis with nasal polyps in patients with coexisting asthma (June 15, 2025)
- FDA approval secured for Dupixent as the only targeted medicine for treating bullous pemphigoid, expanding its therapeutic applications (June 20, 2025)
- CHMP recommendation received for Sarclisa's EU approval to treat transplant-eligible newly diagnosed multiple myeloma (June 23, 2025)
These developments represent significant regulatory and clinical milestones for Sanofi's key drug products, particularly strengthening Dupixent's market position across multiple indications and advancing Sarclisa's potential availability in the EU market for multiple myeloma treatment.